Pete I do not believe the Kevetrin story is over. Below is a study of a Kevetrin modification which reportedly increase its effectiveness 100X.Obvoiously more studies need to be done. Based of the results below I expect a whole series of studies based on these results.

In the present study, we designed and synthesized a novel analog (compound 900) of Kevetrin and its cytotoxicity was assessed using four different ovarian cancer cell lines viz. OVCAR-3, OVCAR-10, ES2, drug-resistant HeyA8 cells, and normal fibroblast cells (FHC). Compared to the control and Kevetrin, compound 900 inhibited the ovarian cancer cell viability in a dose- and time-dependent manner. The IC50 value of compound 900 was 0.8 µM, 0.7 µM, 0.8 µM, and 0.9 µM for OVCAR-3, HeyA8, OVCAR-10, and ES2 cells, respectively, while for Kevetrin the IC50 value was >100 µM for 48 h treatment. Compound 900 was thus found to be >100 times more potent than standard Kevetrin. To further acquaint the effect of 48 h treatment on cell proliferation, we performed trypan blue cell viability assay, trypan blue dye exclusion assay, Annexin V/7-AAD, Caspase 3/7 apoptosis assays, and Western blotting of apoptotic proteins involved in apoptosis. Compound 900 significantly induced apoptosis in OVCAR-3 and HeyA8 cells in a dose-dependent manner. Upregulation of several apoptotic proteins, as evident by Western blot, suggested that 900 causes the induction of apoptotic pathways efficiently. Further, the cell cycle analysis showed a significant arrest of OVCAR-3 and HeyA8 cells in the S-phase, which was further confirmed by the analysis of cyclin A2, cyclin-E1, p21, and p27 protein expression. Additionally, compound 900 caused a significant increase in the expression of the cell cycle inhibitory genes p21 and p27 in a p53-independent manner, compared to Kevetrin. Kevetrin has shown promise in preliminary clinical studies in solid tumor patients. The new analog 900 is >100 fold more potent than Kevetrin and holds great promise to be developed further for ovarian and other mechanistically relevant cancers.

Citation Format: Asif Raza, Jacek Krzeminski, Shantu Amin, Arun Sharma. Discovery of a novel Kevetrin analog as a potential therapeutic for ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1650.

The news in PEL 83 just gets better and better.

Farrell

New England Journal of Medicine study of Paxlovid shows no conclusive benefit in high risk patients.

"Conclusions
The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials.gov number, NCT05011513.)"

"In this trial, we assessed the safety and efficacy of nirmatrelvir–ritonavir as an antiviral agent against SARS-CoV-2 in symptomatic, nonhospitalized, vaccinated or unvaccinated adults. Nirmatrelvir–ritonavir was not associated with a significantly shorter time to sustained alleviation of Covid-19 symptoms than placebo, and the usefulness of nirmatrelvir–ritonavir in patients who are not at high risk for severe Covid-19 has not been established."

Is it time for a Paxlovid vs Brilacidin clinical trial?

Farrell

It was Kevetrin not Brilacidin. It is a shame Kevetrin never made the cut for a clinical trial for retinoblastoma.

https://www.fdanews.com/articles/174349-cellceutixs-kevetrin-wins-rare-pediatric-disease-designation

Farrell

The last published report on STP's EEZ block 4 I could find were from March 2023. The report claims ERHC still controls EEZ block 4.The report acknowledges that ERHC lost its arbitration cases in London and Texas, but STP never forced ERHC to relinquish the block. Kosmos and Total are reported to pay ERHC for "most" of the block, but how much does ERHC now hold and how or how much was it paid?

This report helps understand the confusion regarding the development or the lack there of EEZ block 4. The ambiguity in losing the arbitration but allegedly still controlling at least part of EEZ block 4 certainly should spark speculation about the current situation. Evidently Kosmos's interest in the block is diminished. Total evidently has standing awarded by the STP, but the silence regarding ERHC's position is interesting to say the least; especially in view of the findings in EEZ block 6.

I welcome any updated information anyone can post.

Good luck, Farrell


Sao Tome and Principe
Block 4, eyed by TotalEnergies and Kosmos, still held by US junior ERHC
Published on 15.03.2023 at 04:40 GMT

The Sao Tomé & Principe government formed last November by Prime Minister Patrice Trovoada is looking for a solution to the problem posed by Block 4. Positive results from drilling by Shell and Galp on Block 6 further south last August in turn sparked enthusiasm for Block 4, which is being eyed by TotalEnergies and Kosmos Energy (AI, 09/09/22).

The US junior ERHC, the block's operator, owes significant tax arrears to the state, but the Agência Nacional do Petróleo de São Tomé e Príncipe (ANP-STP) has not decided to withdraw the licence despite having formally notified the firm of its delay. Several arbitrations have been made in the case in favour of Kosmos and TotalEnergies, which had both successively made a deal to purchase most of the ERHC shares on Block 4.

Shell is expected to decide shortly whether to re-drill Block 6 to ascertain its potential. Failure to do so would be bad news for the entire offshore basin where, to date, no commercial discovery has been made. A joint development zone with Nigeria has also not brought any hope, despite interest from TotalEnergies and Chevron.

© Copyright Africa Intelligence. Reproduction and dissemination prohibited (Intranet...) without written permission. - 84052105
Set up email notifications for these topics

Agencia Nacional do Petroleo de Sao Tome e Principe
Chevron
ERHC
Galp
Kosmos Energy
Patrice Trovoada
Shell
TotalEnergies

Further reading
Namibia
Knowledge Katti set to make a killing on TotalEnergies and Shell Orange Basin discoveries

The intuition of Namibia's best-connected businessman, Knowledge Katti, could make him one of the country's richest people. He has positioned one of his firms in the heart of the promising blocks in the Orange Basin.
LogoSubscribers only Energy 12.04.2023
Spotlight | Angola
Manuel Vicente takes Somoil into big league with Lourenco's backing

Angolan junior Somoil has increased its asset portfolio through a number of purchase since the start of last year. Behind this expansion is Manuel Vicente, the oil strategist of former president José Eduardo dos Santos, who is also close to Joao Lourenco.
LogoSubscribers only Energy 28.02.2023
Manuel Vicente at the COP21 World Climate Change Conference 2015, France, 30 November 2015.
Sao Tome and Principe
Shell/Galp's drilling on block 6 may kickstart negotiations over block 4

The offshore field in Sao Tomé has recently become a hotspot for oil companies eagerly awaiting the results of drilling on block 6. If drilling is successful, negotiations over block 4, contested by ERHC, Kosmos and TotalEnergies, may resume.
LogoSubscribers only Energy 09.09.2022
Angola
Galp plans offshore exit to finance cash calls for Africa and Brazil

The Portuguese firm is seeking to divest its interests in two Angolan producing blocks operated by Chevron. It is reorganising its portfolio in order to finance cash calls on its most promising blocks in Africa and in Brazil.
LogoSubscribers only Energy 18.05.2022

Stock up 20% last month with higher oil prices and continued good news ...crossed 50 day moving average. Nice move

GLTA Farrell

Thanks to you and guard dog

Great news with world class partners and world class discoveries on trend with unusually good terms.

$10 million in staged compensation with a 2 well carry plus 17% of a potentially large oil field

AOIFF now at a almost 2 year low in share price.

Now awaiting development plans.

GLTA Farrell

Terrific news! Great deal, excellent terms.

"A large opportunity set of exploration prospects has been identified in deepwater Block 3B/4B and the ability
to stack targets in early wells on the license combined with an extensive data acquisition campaign will help
to significantly understand the prospectivity and presents opportunities for ‘cluster’ developments to
optimize value from any possible developments.
Recent exploration in South Africa has opened a new deepwater play. TotalEnergies made the Brulpadda
gas-condensate discovery on Block 11B/12B in 2019. Prior to this discovery, South Africa's deepwater plays
had seen minimal exploration. Only four deepwater exploration wells had been drilled, in the late 1980s and
early 1990s, in the Southwest coastal basin. TotalEnergies followed the Brulpadda discovery with the Luiperd
discovery in 2020.
Shell Exploration & Production’s (“Shell”) recent Graff well discovery and TotalEnergies Venus well discovery
in deep water Namibia contain seismic amplitude anomalies and are on trend with AOC’s South African
3B/4B license. The discoveries prove the existence of a working petroleum system for light oil, gas
condensate and gas in the geological play fairway. The proven reservoirs in Graff and Venus discoveries are
similar to Cretaceous reservoirs and geological plays that would be targeted in the AOC 3B/4B Exploration
Right.
Block 3B/4B is in water depths ranging between 500 m and 2,500 m with the majority of the prospects lying
in approximately 1,500 m of water. AOC has approximately 14,000 km2 of 2D seismic and 10,800 km2 of 3D
seismic over Block 3B/4B. RISC has reviewed 10,210 km2 of 3D seismic..."

https://africaoilcorp.com/operations/block-3b-4b/

I have picked up more shares I am surprised with the collapse of the share price. I still think AOIFF is the safest way to play the Namibian oil boom. It is obvious it will take years to monetize their holdings, but the demand for oil goes up every year and we seem to be at the crest of peak oil. EV's seemed to have hit the wall; although China's success bears watching.
IMO the patient will be rewarded.We will see,

GLTA, Farrell

Thanks for posting. One can spin this how one likes,but it is definitely another achievement before the full approval.

"estimating up to 10 billion barrels of original oil in place." Video included in link

https://finance.yahoo.com/news/sintana-energy-ceo-confirms-2nd-151232381.html
Sintana Energy CEO Robert Bose shared significant developments regarding the Mopane-1X well during an interview with Steve Darling from Proactive.

According to Bose, Sintana Energy, in partnership with Galp through the AVO-2 consortium, has successfully and safely drilled, cored, and logged a deeper target in the Mopane-1X well, located on block 2813 governed by PEL83 in Namibia.

Bose also revealed that Galp has made another noteworthy discovery within the Mopane-1X well. A second substantial column of light oil has been identified in reservoir-bearing sands of high quality. Following these discoveries, the drilling rig is expected to be relocated to the Mopane-2X well location to further evaluate the extent of the Mopane discoveries. Subsequently, a Drill Stem Test will be conducted in Mopane-1X to assess commercial viability.

Bose highlighted the strategic importance of the Multani 1x location, emphasizing its position as the first well drilled beyond Shell and Total's concentrated efforts. The discoveries, announced on January 10th and 26th, showcased the basin's extensive resources, estimating up to 10 billion barrels of original oil in place.

Sintana Energy maintains an indirect 49% interest in Custos Energy, which holds a 10% working interest in PEL 83. The National Petroleum Company of Namibia (NAMCOR) also maintains a 10% working interest in the project. The consortium partners, including Sintana Energy and Galp, will continue to analyze the acquired data to determine the commercial potential of these discoveries.
Contact Details

Proactive Canada

GLTA Farrell

Great due diligence...once again

Seems to be a serious dude.

JMO but some things up...unfortunately we have to wait again to find out.

GLTA Farrell

From Aoiff web page an extensive review of the entire block 3b-4b

https://africaoilcorp.com/operations/block-3b-4b/

Should be we hit more crude...JMHO

Farrell

The 18% interest per annum is excessive and may be grounds for an appeal. What basis did the judge have for 18% interest added to the judgement? The average prime rate over the last 5 years is closer to 3 to 4 %.

Jmho but the judges over step on the interest may give ipix a temporary breather. Maybe enough to score some points with Bea Med.

We will have to wait and see.

Good luck to all,

Farrell

End of 2023 review of Sintana Energy



Year End Review & Outlook

Since the basin opening Graff and Venus discoveries in February of 2022 by Shell and TotalEnergies respectively, the potential of the Orange Basin in Namibia has continued to emerge.

Officials at Namibia’s Ministry of Mines and Energy and NAMCOR, Namibia’s national oil and gas company, estimate that at least 11 billion barrels of light oil-in-place and up to 8.7 trillion cubic feet of gas-in-place have been discovered by Shell and TotalEnergies over the past 20 months.

Specific notable events in 2023 for Sintana included the following.

Petroleum Exploration License 83
(“PEL 83”)

Initiation in November of a two well drilling campaign, including an optional drill stem test.

Petroleum Exploration License 87 (“PEL 87”)

Entry in March by a subsidiary of Woodside Corp. (“Woodside”) into an agreement whereby in exchange for financing and completing a 5,500 square kilometer 3D seismic program, Woodside would earn the option to become operator with a 56% working interest. Additionally, Woodside will carry the existing working interest owners, including Sintana’s local affiliate, on an initial exploration campaign. Woodside ultimately acquired 6,600 square kilometers of 3D seismic data which was completed in May 2023. Initial fast-tracked results were delivered in Q3 2023.

Petroleum Exploration License 90 (“PEL 90”)

Completion in March of the acquisition of 6,500 square kilometers 3D seismic data by an affiliate of Chevron Corp. (“Chevron”) in March.
In November, the application by Chevron to the Ministry of Environment, Forestry and Tourism for the Republic of Namibia for an Environmental Clearance Certificate which would provide for the drilling of up to 5 exploration and 5 appraisal wells.

The Company expects substantial exploration and evaluation activities to occur throughout 2024, both on and around our offshore blocks including:

Completion of the initial two well drilling campaign by Galp on PEL 83 in Q1.
Delivery of the final results of the 3D seismic analysis by Woodside and the triggering of its option to become operator of PEL 87.
Initiation of a drilling campaign on PEL 90 by Chevron in Q4.
Additional exploration and appraisal activity by both Shell and TotalEnergies in the Orange Basin on their respective blocks which immediately offset blocks in which Sintana has indirect interests.

“The numerous catalysts expected in the coming quarters will provide a number of opportunities to further assess and substantiate the multi-billion barrel potential of the Orange Basin in Namibia,” said Robert Bose. “Specifically for Sintana, we look forward to the progress of drilling and other exploration activities on our blocks unveiling the quality and opportunity associated with our unmatched position in the heart of the basin,” he added.

Management Update

Effective January 1, 2024, Robert Bose will assume the role of Chief Executive Officer and relinquish his role as President. Doug Manner, currently CEO, will assume the role of President. Both Mr. Bose and Mr. Manner will continue to serve on the Company’s Board of Directors.

Incentive Awards

The Company reports that its Board of Directors has approved grants of a total of 5.3 million incentive common stock options to several directors and officers of the Company and four other parties. The options have an exercise price of $0.27, vest in three equal tranches over the next 24 months and will expire on December 19, 2033.

ABOUT SINTANA

The Company is engaged in petroleum and natural gas exploration and development activities on five large, highly prospective, onshore and offshore petroleum exploration licenses in Namibia, and also in Colombia’s Magdalena Basin.

On behalf of Sintana Energy Inc.,

“Douglas G, Manner”
Chief Executive Officer

For additional information or to sign-up to receive periodic updates about Sintana’s projects, and corporate activities, please visit the Company’s website at www.sintanaenergy.com."

https://sintanaenergy.com/news-release/year-end-review-2024-outlook-management-changes-and-2023-incentive-

Mangetti-1X in Venus block may be another huge discovery.

"Mangetti-1X well closes in on target, as enthusiasm grows over two huge new Venus lookalikes in same block
12 January 2024 9:59 GMT Updated 12 January 2024 9:59 GMT
By Iain Esau
in London

TotalEnergies will know within days if its closely watched Mangetti-1X exploration probe offshore Namibia is a success, although the company may keep the results from its latest Orange basin well under wraps until next month.

The French supermajor is also preparing to shoot 3D seismic data over two prospects that could be even bigger than Venus which, according to state oil company..."

Unfortunately I do not subscribe to Upstream. If anyone hears any new regarding Mangetti-1X please update the developments on the board

Namibia becomes more interesting every day.

GLTA Farrell


https://www.upstreamonline.com/exploration/totalenergies-latest-namibia-well-nears-reservoir-as-excitement-builds-over-other-venus-scale-prospects/2-1-1582291

Sintana announces successful drilling on Namibia block 83 . Sintana holds a 10% interest through Custos Energy. Sintana's stock appears to be way under valued.

JMO, Farrell

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Sintana Energy Inc. (TSX-V: SEI, OTCQB: SEUSF) (“Sintana” or the “Company”) is pleased to provide the following update regarding the ongoing exploration campaign on blocks 2813A and 2814B located in the heart of Namibia’s Orange Basin, emerging as the one of the world’s most prospective oil and gas regions. The blocks are governed by Petroleum Exploration License 83 (“PEL 83”) which is operated by a subsidiary of Galp Energia (“Galp”) of Portugal. Sintana maintains an indirect 49% interest in Custos Energy (Pty) Ltd. (together with Custos Investments (Pty) Ltd. “Custos”), a 10% working interest owner in PEL 83. NAMCOR, the National Petroleum Company of Namibia, also maintains a 10% working interest.

https://markets.businessinsider.com/news/stocks/pel-83-exploration-campaign-update-mopane-1x-significant-light-oil-discovery-1032957896?op=1

AOIFF's PR and slide show review of the financial aspectts of de risking Impact Oil's Venus holdings

"Africa Oil Corp. ("Africa Oil", "AOC" or the "Company") is pleased to announce a significant value enhancing farmout transaction related to its offshore Namibia interests held through its investee company, Impact Oil and Gas Limited ("Impact"). On the closing of this transaction Impact will have a 9.5% interest in Blocks 2912 and 2913B (together, "the Blocks") that is fully carried for all joint venture costs, with no cap, through to first commercial production. Impact will also be cash reimbursed on closing for its share of the past costs incurred on the Blocks net to the farmout interests, which is estimated to be approximately USD 99 million. "

https://africaoilcorp.com/news/africa-oil-announces-strategic-farmout-of-impacts-122899/
https://africaoilcorp.com/site/assets/files/1863/impact-farmout-presentation-january-2024-final.pdf

GLTA

Upstream confirms Galp reports

Galp Energia’s successful Mopane-1X exploration well offshore Namibia hit a “substantial” pay zone, according to state oil company Namcor, which has also elaborated on the geology of the discovery.

The Portuguese player announced the discovery yesterday, news that saw the company’s stock price close up 8% on Wednesday at €14.98 ($16.39), before surging to a high of €15.13 in Thursday early morning trading on the Lisbon exchange.
Galp stock price hits four-year high after major oil discovery in Namibia's white-hot Orange basin
Read more

Namcor said Mopane-1X in Block 2813A in which it has a 10% carried interest “confirmed the discovery of a substantial column of light oil in high-quality, reservoir-bearing sands in the Cenomanian-Turonian interval.”

This is the second Upper Cretaceous oil discovery in the Orange basin, said the state-owned player, after Shell’s Graff find, augmenting the Lower Cretaceous oil discoveries made by TotalEnergies and Shell in 2022.

This discovery is a pivotal moment in Namibia’s journey towards becoming an influential player in the global energy market PEL 83 JV

The block partners, which include Namibian player Custos Energy, are set to continue the analysis of the acquired data and carry out a drill stem test in the coming weeks.

Mopane-1X drilling operations will proceed to explore deeper targets within the block and on completion of these operations, the Hercules semi-submersible rig will relocate to the Mopane-2X site to further evaluate the extent of the discovery.

Shiwana Ndeunyema, interim managing director of Namcor, said: “This is an amazing time for Namibia and Namcor. The Mopane-1X discovery is not just a significant achievement for our organisation but also a beacon of hope for the entire nation’s economic future.

“We are immensely pleased with these results and excited about the potential opportunities this opens up for our country.”(Copyright)

My order was a sell. It has filled completely.

I attempted to buy back my shares and received the following note:

"We are not accepting opening orders on Caveat Emptor OTC securities.; No opening transactions are allowed on securities affected by amendments to SEC Rule 15c2-11."

Then the question is who can buy the shares sold through Ameritrade?

Is it farmed out to a third party?

Farrell

All the Ameritrade accounts have transferred except option accounts which will transfer on 11/3/2023.

My Ameritrade sell order filled completely in several transactions the last being yesterday.

Below is copied from my Ameritrade acount

"Your account moves to Schwab the weekend of November 3!
It's time to create your Schwab login info

Any person associated with this account must have their own Schwab Login ID and password
You'll use one login to access all your accounts on all Schwab platforms
Access to your account on TD Ameritrade platforms ends Friday, November 3 at 8:30 p.m. ET"



GLTA, Farrell

Sorry I was in a hurry to run an errand when I answered you the first time.

The trades were both buys and sells. My account does not switch from Ameritrade to Schwab for a few weeks. I am uncertain if Schwab will allow Erhe buys and sells.

Good to see you are still posting.

Farrell

I thought it was both. You may be right.

Farrell

Schwab has acquired Ameritrade. The transfer of all the accounts will be complete in a few weeks.

About 40,000 ... a small percentage of what own. I was primarily interested in testing the Ameritrade trading

ERHE trading on Ameritrade now. Those .0048 shares sold today were mine. I called Ameritrade earlier and they confirmed they were accepting orders.

Whose buying?

Farrell

Brilacidin was studied as an eye drop for bacterial keratitis and was shown to be equivalent to Vancomycin against multiple resistant staph aureus

"Conclusions: BRI has Gram-positive in vitro activity; topical BRI 0.5% was minimally irritating; and BRI 0.5% was equally efficacious as VAN in a MRSA keratitis model when the corneal epithelium was removed. "

https://pubmed.ncbi.nlm.nih.gov/26501484/

Adenoviral keratoconjunctivitis is often referred to as epidemic keratoconjunctivits and out breaks are common world wide. While it can produce severe symptoms it usually resolves in a few weeks and unlike bacterial and fungal keratitis it is not a cause of permanent eye damage or visual loss. Infrequently the symptoms can last for a few months.

To the best of my knowledge Brilacidin has not been tested against Adenoviruses.

Your comment regarding the Brilacidin eye drop has validity. Fungal keratitis is becoming more common in the Northern hemisphere as the world wide temperature has increased. Fungal keratitis is much more common in tropical countries and the southern US, especially Florida.

At times fungal keratitis responds poorly to topical anti-fungal medications and has a higher rate of permanent corneal scarring, permanent visual loss and even loss of the eye. Corneal scarring at times requires corneal transplantation to improve vision.

IMO Brilacidin has a high probability of being approved for fungal diseases and fungal keratitis. The topical eye drop could be the first Brilacidin approved treatment in humans.

Antibiotic, antiviral and antifungal eye drops are all prescription and will require full testing. There is no reason to believe Brilacidin as a topical eye drop will ever be released over the counter in the United States.

Many other countries do allow antibiotics and topical antibiotic eye drops to be dispensed without a prescription. I have been told one can go to Tijuana, Mexico and buy antibiotics without prescriptions.

Good luck,Farrell

New update!
https://finance.yahoo.com/news/sintana-energys-reveals-exciting-updates-170532599.html

Plus...SEUSF has hired a financial...investment banker:

Sintana Energy Inc. Provides Update on Upcoming Communications and Investor Relations Initiatives

"Further, Sintana is pleased to announce the engagement of Auctus Advisors LLP ("Auctus"), a specialist Equity Capital Markets and Advisory firm based in the United Kingdom with a focus on the energy sector. Auctus is owned by its partners who together have decades of experience across Equity Capital Markets, Investment Banking and the Energy industry, having worked previously at Societe Generale, Canaccord Capital, BMO Capital Markets and Schlumberger. Most recently the partners worked together for many years at GMP FirstEnergy.

Auctus will provide capital markets advisory and investor relations services to the Company including enhancing Sintana's communications and investor outreach efforts with a specific focus on Europe.

The initial term of the engagement is for 6 months (subject to extension) with total fees of £30,000. In addition, in the event the retainer continues beyond the original term, the Company shall pay an annual retainer of £60,000. Auctus does not own or control, directly or indirectly, any securities of the Company.

Auctus provides Corporate Broking, Equity Research and Investment Banking services. Auctus is authorised and regulated by the Financial Conduct Authority and is registered in England and Wales under the partnership number OC429983. Its registered address is Robsacks, Long Barn Road, Weald, Sevenoaks, Kent TN14 6NJ."

Investment banking ? Things are heating up.

GLTA,

Farrell

New update from Upstream

"TotalEnergies has completed its closely watched Nara-1X exploration probe offshore Nfarrellamibia, with an announcement thought to be imminent on what could — if successful — be another blockbuster oil discovery."

We should know the results soon.

Fungal disease is becoming more common

"Annually, over 150 million severe cases of fungal infections occur worldwide, resulting in approximately 1.7 million deaths per year. Alarmingly, these numbers are continuously on the rise with a number of social and medical developments during the past decades that have abetted the spread of fungal infections. Additionally, the long-term therapeutic application and prophylactic use of antifungal drugs in high-risk patients have promoted the emergence of (multi)drug-resistant fungi, including the extremely virulent strain Candida auris. Hence, fungal infections are already a global threat that is becoming increasingly severe. In this article, we underline the importance of more and effective research to counteract fungal infections and their consequences."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278517/

"Climate changes in temperature and rainfall are enabling the spread of certain fungal lung diseases beyond their traditional geographic hot spots in the United States, and doctors commonly miss the diagnosis."

https://www.upi.com/Health_News/2022/11/21/fungal-infections-climate-change-study/1171669045633/

As temperatures rise, fungi can develop tolerance for warmer environments — including the bodies of humans and other mammals, whose naturally high temperatures typically keep most fungal pathogens at bay. Over time, humans may lose resistance to these climate-adapting fungi and become more vulnerable to infections. Some researchers think this is what is happening with C. auris.

https://grist.org/health/candida-auris-infections-spread-us-climate-change/

GLTA Farrell

"Shell and TotalEnergies have discovered at least 11 billion barrels of light #oil and up to 8.7 trillion cubic feet of #gas in Namibia’s prolific Orange basin over the last 18 months, according to top petroleum officials in the country."

Upstream

Looks like penny flippers have discovered our stock running the price up and down for a few hundred dollars.

I am not interested in playing.

GLTA Farrell

Thanks for the reminder.
Subhash Dhawan is an impressive individual with the right experience,credentials and background to advance Brilacidin and his device to a clinical trial.

JMHO, Farrell

Thanks for posting

2023:

BASILEA HALF-YEAR REPORT 202318
OUTLOOK:
BASILEA HALF-YEAR REPORT 202318
OUTLOOK pg 18

Upcoming milestones
H2 2023
In-licensing or acquisition of novel anti-infectives
to complement clinical pipeline
H1 2024
In-licensing or acquisition of novel anti-infectives
to complement clinical pipeline

Interesting they are making announcing corporate goal to acquire or license novel, complementary antiinfectives.

I do not know Basilea well enough to outline all the drugs they may be evaluating, but it is a sure bet Brilacidin is one of them.

JMHO, Farrell

Another recent outbreak of Marburg virus is causing concern. Currently no antiviral treatment is available for Marburg virus. The death rate is as high as 80%.

Marburg virus is a Filovirus. "The Filoviridae consists of 2 genera: Ebolavirus (consisting of 5 species) and Marburgvirus (consisting of 2 species). The specific vectors of these viruses have not been confirmed, but fruit bats are the prime candidates; thus, Filoviridae are not arboviruses. Human-to-human transmission of Ebola virus and Marburg virus occurs readily."

https://www.merckmanuals.com/professional/infectious-diseases/arboviruses,-arenaviridae,-and-filoviridae/overview-of-arbovirus,-arenavirus,-and-filovirus-infections

Brilacidin may have activity against Filoviruses: "...earlier NIH/NIAID-affiliated research of Brilacidin in other acutely infectious virus families, including coronaviruses, alphaviruses, flaviviruses, and filoviruses, with a corresponding scientific paper being prepared for publication."
https://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox

https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease
https://www.cdc.gov/locs/2023/04-06-2023-Lab-Advisory-CDC_Issues_CDC_Issues_Health_Alert_Marburg_Disease_Outbreaks.html
https://www.mirror.co.uk/news/health/deadly-virus-turns-sufferers-into-30520661
cnn.com/2023/04/06/health/cdc-alert-marburg/index.html

"In summary, we identified five molecules,
Hayatinine, Bedaquiline, Brilacidin, Curine, and MMV688271 that completely blocked invasion/schizont rupture at IC50"

Thanks for posting. This finding is consistent with Polymedix's lab findings that some of their small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides had an inhibitory affect against malaria.

This study confirms Brilacidin also possesses antimalarial inhibitory effects. Brilacidin is truly a multifaceted compound with proven antibacterial,antiviral,antifungal and now antiparasitic antimalarial effects.

GLTA Farrell

Sorry I missed your reply.

By focusing on the mortality numbers you ignored a number of significant complications of viral encephalitis plus you did not bother to mention the fact that Brilacidin has been shown to have activity against other viral disorders and other strains of encephalitis.

"Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.

The in vitro evaluation of Brilacidin’s antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin’s effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes."

https://www.ipharminc.com/press-release/2022/9/14/new-in-vitro-data-supporting-the-broad-spectrum-antiviral-activity-of-innovation-pharmaceuticals-brilacidin-presented-at-2022-military-health-system-research-symposium

Below are some facts relating to Eastern equine encephalitis
No vaccine
No antiviral treatment
41% death rate
50% neurological complications such as: psychosis, memory loss,seizures

"Several complications have been described, more frequently involving the central nervous system resulting in cognitive, motor, or sensory deficits. Associated neurological sequelae include most commonly seizures (63%), but also paralysis, intellectual disability, and behavioral changes. Late diagnosis and intervention can result in multiorgan failure and autonomic dysfunction, and ultimately death.[20][21] A rare case reported hemophagocytic lymphohistiocytosis in a 5 month-old infant secondary to EEE.[22] Behavioral changes are also described, specifically psychosis."

https://www.ncbi.nlm.nih.gov/books/NBK557692/

Venezuiian equine encephalitis can occur as large outbreaks affecting thousands of individuals. It is more common in Central and South America While it is rarely reported in the US. It should be of concern to travelers to endemic areas. One outbreak in South America record 13,000 individual infections.
The disease has a lower death rate and neurological complication rate than EEE, but shares many clinical features.
https://www.ncbi.nlm.nih.gov/books/NBK559332/



:

The FDA process for approving medical devices can be much less stringent than pharmaceuticals.

BeaMedical Technologies {IPIX' has about a 40% position} has received clearance fro the Manta family of surgical lasers
11/2022
"BT BeaMedical Technologies (“BeaMed”), a private company developing a next-generation laser-based platform for epilepsy and cancer surgery, has notified Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) that it has received U.S. Food and Drug Administration (FDA) clearance (K222701) for its MANTA surgical laser family. The clearance is an important milestone for BeaMed in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality. Innovation Pharmaceuticals made a strategic investment to acquire a minority stake in BeaMed in June 2022."

"he MANTA surgical laser family was cleared by the FDA including five different wavelengths (810nm, 980nm, 1064nm, 1470nm and 1940nm) and soft tissue use in a very wide set of clinical specialties, including Neurosurgery, Spinal Surgery, Urology, Thoracic Surgery, Pulmonary Surgery, Gynecology, General Surgery, ENT/Head and Neck, Plastic Surgery, Orthopedics, Arthroscopy, Ophthalmology, Radiology, and Oral Surgery."

The next approval is for the fiber optic delivery system and integration with MRI imaging.

2/2023
"Having already obtained FDA clearance for the laser component of the StingRay
System, BeaMed expects soon to make additional requisite submissions to the
FDA for clearance of its fiber optics and its software integration package
with Siemens and GE imaging systems."

ttps://www.bloomberg.com/press-releases/2023-02-23/innovation-pharmaceuticals-visits-beamed-new-stingray-laser-system-for-epilepsy-and-brain-tumors-moving-toward-fda-submission

In addition Beamed has signed an agreement with Shina Systems to facilitate development and regulatory approval:

1/2023
"BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd. (“Shina”), a company specializing in medical imaging software platforms, in order to build on unique capabilities of Shina and accelerate the development, regulatory clearance, and commercial deployment of BeaMed’s StingRay Laser System for brain surgery."

“This agreement provides us with two key strategic advantages,” said Gil Shapira, Chief Executive Officer of BeaMed. “The first is immediate access to decades of experience and knowledge regarding design and implementation of high end medical imaging platforms including MRI access, 3D image processing and visualization, and superlative usability. The second is acceleration of our development timeline to get through FDA clearance and market launch quickly. This path underscores the execution-focused strategy of BeaMed to successfully bring its innovation to the market efficiently and expeditiously.”

"Shina Systems Ltd. develops and markets clinical image management, PACS and medical imaging analysis application software for almost 3 decades. Shina is recognized for its unique tools and intuitive, clinician-friendly application workflow. Clinically effective and technologically distinguished, Shina’s software is installed in thousands of clinical sites worldwide, including OEM partners from the top 10 global medical imaging and equipment companies."

My guess is that approval could come within months.

GLTA, Farrell

Very interesting. Thanks for posting . More evidence to support Brilacin's anti -infective possibilities...antiviral, anti fungal, antibacterial.

Good luck,

Farrell